MBIO Stock Overview A clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. More details
Rewards Risk Analysis + 4 more risks
See All Risk Checks Capture your thoughts, links and company narrative
Mustang Bio, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Mustang Bio Historical stock prices Current Share Price US$0.26 52 Week High US$1.52 52 Week Low US$0.13 Beta 1.77 1 Month Change 32.75% 3 Month Change 19.24% 1 Year Change -82.42% 3 Year Change -98.86% 5 Year Change -99.60% Change since IPO -99.83%
Recent News & Updates
Mustang Bio, Inc., Annual General Meeting, Dec 26, 2024 Dec 09 Nasdaq Hearings Panel Grants Mustang Bio's Request for an Extension Through January 31, 2025, to Demonstrate Compliance with the Bid Price Rule, and Through February 18, 2025, to Demonstrate Compliance with the Equity Rule
Listing Qualifications Department of Nasdaq Determines to Delist the Mustang Bio's Securities from Nasdaq Sep 15 Listing Qualifications Department of Nasdaq Determines to Delist the Mustang Bio's Securities from Nasdaq Sep 14
New major risk - Market cap size Sep 12
New major risk - Financial position Aug 15 See more updates
Mustang Bio, Inc., Annual General Meeting, Dec 26, 2024 Dec 09 Nasdaq Hearings Panel Grants Mustang Bio's Request for an Extension Through January 31, 2025, to Demonstrate Compliance with the Bid Price Rule, and Through February 18, 2025, to Demonstrate Compliance with the Equity Rule
Listing Qualifications Department of Nasdaq Determines to Delist the Mustang Bio's Securities from Nasdaq Sep 15 Listing Qualifications Department of Nasdaq Determines to Delist the Mustang Bio's Securities from Nasdaq Sep 14
New major risk - Market cap size Sep 12
New major risk - Financial position Aug 15
New major risk - Market cap size Aug 06 Mustang Bio, Inc. has filed a Follow-on Equity Offering in the amount of $2.51299 million. Jun 21
Mustang Bio, Inc. has completed a Follow-on Equity Offering in the amount of $5.6 million. Jun 20
Mustang Bio, Inc. Announces Favorable Efficacy and Safety Data from Complete Waldenstrom Macroglobulinemia Cohort of Phase 1/2 Clinical Trial of Mb-106, Cd20-Targeted Autologous Car-T Therapy Jun 18
New major risk - Shareholder dilution May 23
Mustang Bio Receives Notice from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement Under Nasdaq Listing Rule 5550(a)(2) for Continued Listing on the Nasdaq Capital Market May 22
Price target decreased by 43% to US$10.00 May 14 Mustang Bio, Inc. has completed a Follow-on Equity Offering in the amount of $3.998428 million.
New minor risk - Share price stability Apr 04
Mustang Bio, Inc Announces Vision for CAR T-Cell Therapy Platform Expansion into Autoimmune Diseases Mar 28
Mustang Bio Receives Deficiency Letter from Nasdaq Due to Non-Compliance with the Minimum Stockholders’ Equity Requirement Under Nasdaq Listing Rule 5550(b)(1) Mar 18
New major risk - Market cap size Mar 17 Mustang Bio, Inc. has filed a Follow-on Equity Offering in the amount of $10.5 million. Mar 16
New major risk - Financial position Mar 12
Mustang Bio, Inc. Announces Publication in Nature Medicine of Data from Phase 1 Trial Evaluating MB-101IL13Ra2-targeted CAR T-Cells in High-Grade Glioma Mar 07 Mustang Bio, Inc. Appoints Peter Carney as the Interim Chief Accounting Officer
Price target decreased by 29% to US$13.00 Nov 16 Mustang Bio, Inc. announced that it has received $4.742942 million in funding Nov 04
New minor risk - Share price stability Nov 01
New major risk - Revenue and earnings growth Oct 30
Mustang Bio, Inc. Announces FDA Acceptance of IND Application for MB-109, A Novel Combination of MB-101 (IL13RA2-Targeted Car-T Cell Therapy) and MB-108 (HSV-1 Oncolytic Virus), for the Treatment of Recurrent Glioblastoma and High-Grade Astrocytoma Oct 27
Mustang Bio, Inc. Announces First Data from Ongoing Multicenter Phase 1/2 Clinical Trial Evaluating MB-106 CAR-T Cell Therapy Aug 17
uBriGene (Boston) Biosciences Inc. completed the acquisition of Worcester manufacturing facility of Mustang Bio, Inc. Aug 01
Mustang Bio Announces Final Results from Follicular Lymphoma Cohort of Single-Institution Phase 1/2 Clinical Trial of MB-106, CD20-Targeted Autologous CAR T Therapy Jun 16
Consensus EPS estimates upgraded to US$5.61 loss May 25
Price target decreased by 35% to US$40.75 May 24
Consensus EPS estimates fall by 286% May 22
Price target increased by 20% to US$75.00 May 21
uBriGene (Boston) Biosciences Inc. entered into asset purchase agreement to acquire Worcester manufacturing facility of Mustang Bio, Inc. for $11 million. May 19
Mustang Bio, Inc. Provides CAR T Cell Therapy Portfolio Updates and 2023 Anticipated Milestones Dec 20
Price target decreased to US$5.00 Nov 16
Insufficient new directors Nov 16
Mustang Bio Announces First Patient Treated in Its Multicenter Phase 1/2 Clinical Trial of Mb-106, A First-In-Class Cd20-Targeted, Autologous Car T Cell Therapy to Treat B-Cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia Oct 07
Mustang Bio: This Horse May Gallop Still Sep 23
Is Mustang Bio, Inc. (NASDAQ:MBIO) Trading At A 46% Discount? Aug 09
Mustang Bio Announces First Patient Successfully Treated by Ex Vivo Lentiviral Gene Therapy to Treat Rag1 Severe Combined Immunodeficiency Jul 28
Mustang Bio, Inc. Announces Updated Interim Results from Follicular Lymphoma Cohort of Ongoing Phase 1/2 Clinical Trial of MB-106, CD20-Targeted CAR T Therapy Jun 14
Mustang Bio Receives Letter from the Listing Qualifications Staff of Nasdaq Jun 01
Mustang Bio, Inc. Announces Updated Interim Data on X-Linked Severe Combined Immunodeficiency Treatment with Lentiviral Vector Gene Therapy Support Upcoming Multicenter Pivotal Phase 2 Trial for MB-107 May 20
Price target decreased to US$7.40 May 13
Mustang Bio, Inc. Announces Results from Follicular Lymphoma Cohort of Ongoing Phase 1/2 Clinical Trial of MB-106, CD20-Targeted CAR T Therapy, Selected for Oral Presentation at European Hematology Association 2022 Hybrid Congress May 13
Mustang Bio, Inc. Announces Data on Treatment with Lentiviral Viral Vector Gene Therapy for X-Linked Severe Combined Immunodeficiency Selected for Oral Presentation at American Society of Gene & Cell Therapy 25th Annual Meeting May 04
Mustang Bio: The Market Is Missing This Opportunity May 03
Mustang Bio, Inc., Annual General Meeting, Jun 21, 2022 May 02
Insufficient new directors Apr 27
Mustang Bio Inc. Announces Updated Interim Phase 1/2 Data for Mb-106, Cd20-Targeted Car T Therapy, in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia Apr 26
Mustang Bio, Inc. Appoints Eliot M. Lurier as Interim Chief Financial Officer Apr 23
Mustang Bio, Inc. Announces Phase 1 Clinical Trial Combining MB-101 and MB-108 for the Treatment of Glioblastoma Apr 14
Mustang Bio Provides an Update on its IND Application for MB-207, a Lentiviral Gene Therapy for Treatment of X-linked Severe Combined Immunodeficiency in Previously Transplanted Patients Jan 25
Price target decreased to US$8.40 Jan 25
Mustang Bio Announces MB-106 CD20-Targeted CAR T Data Selected for Presentation at the 2022 Tandem Meetings I Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR Jan 09
Will Mustang Bio (NASDAQ:MBIO) Spend Its Cash Wisely? Dec 29
Price target decreased to US$9.80 Nov 17
Mustang Bio Announces MB-101 (IL13Ra2-targeted CAR T cells) Scientific Presentations at Upcoming Virtual Conferences Oct 01
Mustang Bio: Remains Underfollowed Despite Moving Closer To Pivotal Studies Sep 14
President recently bought US$251k worth of stock Aug 06
Mustang Bio, Inc. Receives European Medicines Agency PRIME Designation for MB-107 to Treat X-Linked Severe Combined Immunodeficiency in Newly Diagnosed Infants Aug 04 Mustang Bio, Inc.(NasdaqGM:MBIO) dropped from Russell 2500 Growth Index
Mustang Bio (MBIO) EHA Investor Presentations - Slideshow Jun 18
Mustang Bio Announces Updated Interim Phase 1/2 Data for MB-106 CD20-Targeted CAR T in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphomas and Chronic Lymphocytic Leukemia Jun 12
Mustang Bio jumps 7% on encouraging MB-106 safety and efficacy data in blood cancers Jun 11
Checking Back In On Mustang Bio May 26
Mustang Bio and City of Hope Announce First Patient Dosed in Phase 1 Clinical Trial of MB-101 to Treat Leptomeningeal Brain Tumors May 19
Mustang Bio Announces MB-106 CD20-Targeted CAR T Data Selected for Presentation at European Hematology Association 2021 Virtual Congress May 13
Mustang Bio, Inc. Announces FDA Acceptance of IND Application for MB-106, a CD20-Targeted CAR T Therapy May 11
FDA accepts Mustang Bio's MB-106 application in cancer May 10
Key Executive recently sold US$66k worth of stock Apr 17
Here's Why We're Watching Mustang Bio's (NASDAQ:MBIO) Cash Burn Situation Mar 22
What Type Of Shareholders Own The Most Number of Mustang Bio, Inc. (NASDAQ:MBIO) Shares? Feb 23
Mustang Bio Provides Updates on its Lentiviral Gene Therapies for the Treatment of X-linked Severe Combined Immunodeficiency Feb 03 Shareholder Returns MBIO US Biotechs US Market 7D 17.6% -2.1% -2.1% 1Y -82.4% -8.3% 21.3%
See full shareholder returns
Return vs Industry: MBIO underperformed the US Biotechs industry which returned -8.3% over the past year.
Return vs Market: MBIO underperformed the US Market which returned 21.3% over the past year.
Price Volatility Is MBIO's price volatile compared to industry and market? MBIO volatility MBIO Average Weekly Movement 14.7% Biotechs Industry Average Movement 11.2% Market Average Movement 6.4% 10% most volatile stocks in US Market 18.9% 10% least volatile stocks in US Market 3.2%
Stable Share Price: MBIO's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: MBIO's weekly volatility has decreased from 70% to 15% over the past year, but is still higher than 75% of US stocks.
About the Company Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors. The company develops MB-117 and MB-217, a gene therapy program for X-linked severe combined immunodeficiency, a rare genetic immune system condition in which affected patients do not live beyond infancy without treatment.
Show more Mustang Bio, Inc. Fundamentals Summary How do Mustang Bio's earnings and revenue compare to its market cap? MBIO fundamental statistics Market cap US$12.24m Earnings (TTM ) -US$23.42m Revenue (TTM ) n/a
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) MBIO income statement (TTM ) Revenue US$0 Cost of Revenue US$0 Gross Profit US$0 Other Expenses US$23.42m Earnings -US$23.42m
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/01/12 09:39 End of Day Share Price 2025/01/10 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Mustang Bio, Inc. is covered by 6 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Mayank Mamtani B. Riley Securities, Inc. Justin Zelin B. Riley Securities, Inc. Jonathan Aschoff B. Riley Wealth
Show 3 more analysts 
